Deciphera Pharmaceuticals, Llc

This study tests a new drug, ripretinib, against the current standard sunitinib in people with advanced gastrointestinal stromal tumor (GIST) whose cancer has a specific genetic change (KIT exon 11 plus 17 or 18) and has stopped responding to the first treatment, imatinib. About …

This study tests an experimental drug called vimseltinib in people with advanced solid tumors or a rare joint tumor called tenosynovial giant cell tumor (TGCT). The goal is to find the safest dose and see if it shrinks tumors or improves symptoms. About 120 adults will take part,…

This study tests an experimental drug called vimseltinib for people with tenosynovial giant cell tumor (TGCT), a rare, non-cancerous growth in the joints that causes pain and stiffness. It is for patients whose tumors cannot be removed by surgery. Participants receive either vims…

This study tests a new drug, ripretinib, against the current standard drug, sunitinib, in people with advanced gastrointestinal stromal tumor (GIST) whose cancer worsened after initial treatment with imatinib. About 453 adults with GIST are randomly assigned to take either ripret…